Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Toripalimab in Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
NCT03946943Phase 2Unknown
- Start
- Jul 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in undifferentiated pleomorphic sarcoma (UPS). Status: unknown.
02
Drugs
anlotinib
03
Conditions
undifferentiated pleomorphic sarcoma (UPS)
Beyond the preview
Go deeper on NCT03946943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946943.